Scarica l'app Stockscreener
1.57
1.57%
-0.025
Dopo l'orario di chiusura:
1.59
0.02
+1.27%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PACB Giù?
Forum
Previsione
Precedente Chiudi:
$1.595
Aprire:
$1.69
Volume 24 ore:
13.23M
Relative Volume:
1.46
Capitalizzazione di mercato:
$429.97M
Reddito:
$188.87M
Utile/perdita netta:
$-400.38M
Rapporto P/E:
-1.2362
EPS:
-1.27
Flusso di cassa netto:
$-260.90M
1 W Prestazione:
-36.18%
1M Prestazione:
-20.71%
6M Prestazione:
-22.28%
1 anno Prestazione:
-81.31%
Intervallo 1D:
$1.57
$1.69
Intervallo di 1 settimana:
$1.56
$2.66
Portata 52W:
$1.16
$10.65
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Nome
Pacific Biosciences Of California Inc
Settore
Industria
Telefono
650-521-8000
Indirizzo
1305 O'BRIEN DRIVE, MENLO PARK, CA
Confronta PACB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| PACB | 1.57 | 429.97M | 188.87M | -400.38M | -260.90M | -1.27 |
| ABT | 117.36 | 202.64B | 41.22B | 5.77B | 6.49B | 2.94 |
| SYK | 389.40 | 150.72B | 21.97B | 3.59B | 3.21B | 6.74 |
| BSX | 90.45 | 133.82B | 15.91B | 1.79B | 1.89B | 0.82 |
| MDT | 87.59 | 112.98B | 32.58B | 3.93B | 5.15B | 2.71 |
| EW | 69.89 | 40.52B | 6.60B | 4.16B | 490.10M | 2.34 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-12-14 | Iniziato | Guggenheim | Neutral |
| 2023-12-14 | Iniziato | Stephens | Overweight |
| 2023-12-13 | Iniziato | Wolfe Research | Peer Perform |
| 2023-11-17 | Aggiornamento | UBS | Neutral → Buy |
| 2023-10-31 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-06-30 | Iniziato | Goldman | Buy |
| 2023-05-10 | Iniziato | Barclays | Equal Weight |
| 2023-03-31 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | Iniziato | UBS | Neutral |
| 2023-01-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-01-21 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-01-06 | Ripresa | Piper Sandler | Neutral |
| 2021-10-15 | Ripresa | Cowen | Market Perform |
| 2021-09-27 | Iniziato | Canaccord Genuity | Buy |
| 2021-02-11 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-06-02 | Ripresa | Cantor Fitzgerald | Overweight |
| 2020-03-09 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-10-15 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | Iniziato | Cowen | Outperform |
| 2017-11-03 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | Downgrade | CL King | Buy → Neutral |
| 2016-11-03 | Reiterato | Cantor Fitzgerald | Buy |
| 2016-06-27 | Iniziato | CL King | Buy |
| 2016-04-15 | Iniziato | First Analysis Sec | Overweight |
| 2016-02-04 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | Reiterato | Cantor Fitzgerald | Buy |
| 2015-10-23 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-02-04 | Reiterato | Maxim Group | Buy |
| 2013-09-26 | Reiterato | Maxim Group | Buy |
| 2013-01-14 | Reiterato | Maxim Group | Buy |
Mostra tutto
Pacific Biosciences Of California Inc Borsa (PACB) Ultime notizie
Sumitomo Mitsui Trust Group Inc. Cuts Stock Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
FY2024 EPS Estimates for PACB Lowered by Cantor Fitzgerald - MarketBeat
DNA Sequencing Market to Grow by USD 17.34 Billion (2024-2028), Driven by Rising NGS Adoption, AI-Powered Report Explores Market EvolutionTechnavio - The Malaysian Reserve
Pacific Biosciences of California (NASDAQ:PACB) Upgraded by UBS Group to "Hold" Rating - MarketBeat
Pacific Biosciences CCO departs amid restructuring By Investing.com - Investing.com Australia
Pacific Biosciences CCO departs amid restructuring - Investing.com India
PACB Stock Falls Despite Q3 Earnings Beat, Revenues Decline Y/Y - MSN
Pacific Biosciences' Cost Cuts Won't Offset Rising Competition (NASDAQ:PACB) - Seeking Alpha
Pacific Biosciences of California Inc (PACB) Quarterly 10-Q Report - Quartz
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - The Motley Fool
Pacific Biosciences of California (NASDAQ:PACB) Trading Up 5.3% Following Analyst Upgrade - MarketBeat
Pacific Biosciences of California Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
UBS Downgrades Pacific Biosciences of California (PACB) - MSN
Pacific Biosciences of California (PACB) Reports Q3 Loss, Misses Revenue Estimates - MSN
Cathie Wood's ARK sells Unity, buys Pacific Biosciences stock By Investing.com - Investing.com Nigeria
Cathie Wood's ARK sells Unity, buys Pacific Biosciences stock - Investing.com
PacBio’s $459 Million Convertible Note Exchange Offering - Global Legal Chronicle
Scotiabank Lowers Pacific Biosciences of California (NASDAQ:PACB) Price Target to $6.00 - MarketBeat
Pacific Biosciences of California Target of Unusually High Options Trading (NASDAQ:PACB) - MarketBeat
Pacific Biosciences of California (NASDAQ:PACB) Rating Lowered to "Neutral" at UBS Group - MarketBeat
Pacific Biosciences of California (NASDAQ:PACB) Price Target Raised to $2.50 - MarketBeat
Earnings Update: Pacific Biosciences of California, Inc. (NASDAQ:PACB) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts - Yahoo Finance
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q3 2024 Earnings Call Transcript - Insider Monkey
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Wilson Sonsini Advises PacBio on $459 Million Convertible Note Exchange - Wilson Sonsini
PacBio to Present at 4 Major Healthcare Investor Conferences Through Year-End | PACB Stock News - StockTitan
Pacific Biosciences of California Inc (PACB) Q3 2024 Earnings Ca - GuruFocus.com
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap DownShould You Sell? - MarketBeat
Pacific Biosciences of California Inc (PACB) Q3 2024 Earnings Call Highlights: Navigating ... By GuruFocus - Investing.com Canada
Pacific Biosciences of California Inc (PACB) Q3 2024 Earnings Call Highlights: Navigating ... - Yahoo Finance
Pacific Biosciences: Q3 Earnings Snapshot - CTPost
Pacific Biosciences of California (FRA:P09) 5-Day RSI : 64.86 (As of Nov. 08, 2024) - GuruFocus.com
PacBio stock falls 16% post-market after Q3 revenue miss - MSN
Pacific Biosciences of California, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Pacific Biosciences of California Inc (PACB) Q3 2024 Earnings: E - GuruFocus.com
PacBio Announces Third Quarter 2024 Financial Results - GlobeNewswire
PacBio Announces a Private Convertible Exchange Transaction of $459 Million Principal Amount of 1.50% Convertible Senior Notes due 2028 - StockTitan
Strong week for Pacific Biosciences of California (NASDAQ:PACB) shareholders doesn't alleviate pain of three-year loss - Simply Wall St
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Stock Rockets 56% But Many Are Still Ignoring The Company - Simply Wall St
PacBio Unveils the Vega System, a New Sequencing Platform Bringing HiFi to the Benchtop - StockTitan
Pacific Biosciences of California Inc (PACB) Q3 2024 Earnings Re - GuruFocus.com
Vanguard Group Inc's Strategic Reduction in Pacific Biosciences of California Inc - GuruFocus.com
Reasons to Retain PacBio Stock in Your Portfolio for Now - MSN
Curious about Pacific Biosciences (PACB) Q3 Performance? Explore Wall Street Estimates for Key Metrics - Yahoo Finance
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Pacific Biosciences of California (PACB) Advances While Market Declines: Some Information for Investors - Yahoo Finance
Pacific Biosciences of California (PACB) Scheduled to Post Earnings on Thursday - MarketBeat
Pacific Biosciences (PACB): Promising Gene Editing Stock With Innovating Technology - Insider Monkey
Volta Labs joins PacBio Compatible program to help PacBio customers scale sequencing through automated library prep - Quantisnow
Volta Labs joins PacBio Compatible program to help PacBio customers scale sequencing through automated library prep – Company AnnouncementFT.com - Financial Times
Pacific Biosciences of California (NASDAQ:PACB) Shares Up 5.7%Should You Buy? - MarketBeat
Pacific Biosciences Of California Inc Azioni (PACB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.38%
0.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):